The host—tumor immune conflict: from immunosuppression to resistance and destruction

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1996 • 1,908 citations

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1988 • 1,698 citations

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

1986 • 1,617 citations

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

1996 • 1,281 citations

The origin and function of tumor-associated macrophages

1992 • 1,081 citations

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1996 • 1,001 citations

TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights

1990 • 992 citations

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

1996 • 894 citations

A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen

1993 • 857 citations

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

1989 • 775 citations

Fas ligand in human serum

1996 • 682 citations

Identification of human cancers deficient in antigen processing.

1993 • 625 citations

Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis

1997 • 584 citations

Inhibition of cytokine production by cyclosporin A and transforming growth factor beta.

1987 • 466 citations

Inflammatory and immunomodulatory roles of TGF-β

1989 • 450 citations

Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas

1989 • 420 citations

A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact

1990 • 409 citations

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1997 • 403 citations

Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.

1989 • 391 citations

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

1997 • 342 citations

Costimulation of T cells for tumor immunity

1993 • 324 citations

Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.

1994 • 314 citations

Interleukin-10

1992 • 303 citations

Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells.

1988 • 298 citations

TUMOUR NECROSIS FACTOR AS AN AUTOCRINE TUMOUR GROWTH FACTOR FOR CHRONIC B-CELL MALIGNANCIES

1988 • 282 citations

TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice.

1996 • 274 citations

Perforin-Mediated Target Cell Lysis by Cytolytic T Lymphocytes

1990 • 268 citations

The role of FasL-induced apoptosis in immune privilege

1997 • 262 citations

Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?

1994 • 245 citations

Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expression

1993 • 245 citations

Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor

1993 • 239 citations

Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

1993 • 233 citations

Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.

1996 • 207 citations

Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.

1996 • 195 citations

Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors.

1995 • 190 citations

Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.

1995 • 180 citations

Cytokines, tumour-cell death and immunogenicity: a question of choice

1997 • 168 citations

Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice.

1989 • 164 citations

Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression.

1990 • 159 citations

Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.

1991 • 156 citations

Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.

1996 • 123 citations

The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor‐infiltrating lymphocytes

1994 • 115 citations

Enzymatic activity of the conserved core of a group I self-splicing intron

1986 • 114 citations

Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells.

1993 • 113 citations

Alteration of the Sphingomyelin/Ceramide Pathway Is Associated with Resistance of Human Breast Carcinoma MCF7 Cells to Tumor Necrosis Factor-α-mediated Cytotoxicity

1997 • 106 citations

Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis.

1993 • 102 citations

Maintenance of clonal anergy by endogenously produced IL-10

1994 • 101 citations

Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.

1996 • 100 citations

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses

1995 • 89 citations

Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.

1994 • 80 citations

Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor.

1995 • 77 citations

Functional interaction between TGF-beta and IL-12 in human primary allogeneic cytotoxicity and proliferative response.

1997 • 65 citations

Role of interleukin-6 in paraneoplastic thrombocytosis [letter]

1993 • 62 citations

More insights into the complex physiology of TNF

1991 • 59 citations

Tumor necrosis factor as an autocrine growth factor for neuroblastoma.

1992 • 53 citations

Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

1993 • 45 citations

Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells

1996 • 45 citations

Inhibitory cytokine circuits involving transforming growth factor-beta, interferon-gamma, and interleukin-2 in human monocyte activation

1994 • 23 citations

Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large- cell non-Hodgkin's lymphomas [letter; comment]

1995 • 17 citations

More insights into the complex physiology of TNF

1991 • 14 citations